Combined Transplantation of Unmanipulated Haploidentical and a SingleCord Blood Unit for Patients With Hematologic Malignancies
Interventional
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cord Blood Engraftment
Detectable cord blood engraftment should be present by day 100 in at least 50% of patients.
100 days
No
Andrew Artz, MD
Principal Investigator
University of Chicago
United States: Institutional Review Board
10-020-B
NCT01359254
April 2010
June 2012
Name | Location |
---|---|
University of Chicago | Chicago, Illinois 60637 |